Anti-alpha synuclein binding molecules
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 28, 2019
Grant Date -
Dec 13, 2018
app pub date -
Mar 7, 2018
filing date -
Jun 23, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully